229 related articles for article (PubMed ID: 15625120)
1. Normal and oncogenic forms of the receptor tyrosine kinase kit.
Lennartsson J; Jelacic T; Linnekin D; Shivakrupa R
Stem Cells; 2005; 23(1):16-43. PubMed ID: 15625120
[TBL] [Abstract][Full Text] [Related]
2. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
[TBL] [Abstract][Full Text] [Related]
3. Signal transduction by several KIT juxtamembrane domain mutations.
Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
[TBL] [Abstract][Full Text] [Related]
4. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
[TBL] [Abstract][Full Text] [Related]
5. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
Ali S; Ali S
Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
[TBL] [Abstract][Full Text] [Related]
6. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction via the stem cell factor receptor/c-Kit.
Rönnstrand L
Cell Mol Life Sci; 2004 Oct; 61(19-20):2535-48. PubMed ID: 15526160
[TBL] [Abstract][Full Text] [Related]
9. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
[TBL] [Abstract][Full Text] [Related]
10. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor.
Samayawardhena LA; Hu J; Stein PL; Craig AW
Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778
[TBL] [Abstract][Full Text] [Related]
11. Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation.
Edling CE; Pedersen M; Carlsson L; Rönnstrand L; Palmer RH; Hallberg B
Br J Haematol; 2007 Jan; 136(2):260-8. PubMed ID: 17156394
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.
Yuzawa S; Opatowsky Y; Zhang Z; Mandiyan V; Lax I; Schlessinger J
Cell; 2007 Jul; 130(2):323-34. PubMed ID: 17662946
[TBL] [Abstract][Full Text] [Related]
13. A new twist in the transmembrane signaling tool-kit.
Lemmon MA; Ferguson KM
Cell; 2007 Jul; 130(2):213-5. PubMed ID: 17662934
[TBL] [Abstract][Full Text] [Related]
14. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.
Kim SY; Kang JJ; Lee HH; Kang JJ; Kim B; Kim CG; Park TK; Kang H
Biochem Biophys Res Commun; 2011 Jul; 410(2):224-8. PubMed ID: 21640708
[TBL] [Abstract][Full Text] [Related]
16. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors.
Tabone-Eglinger S; Subra F; El Sayadi H; Alberti L; Tabone E; Michot JP; Théou-Anton N; Lemoine A; Blay JY; Emile JF
Clin Cancer Res; 2008 Apr; 14(8):2285-94. PubMed ID: 18413817
[TBL] [Abstract][Full Text] [Related]
17. Targeting c-Kit mutations: basic science to novel therapies.
Sattler M; Salgia R
Leuk Res; 2004 May; 28 Suppl 1():S11-20. PubMed ID: 15036937
[TBL] [Abstract][Full Text] [Related]
18. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
19. The biology of Kit in disease and the application of pharmacogenetics.
Akin C; Metcalfe DD
J Allergy Clin Immunol; 2004 Jul; 114(1):13-9; quiz 20. PubMed ID: 15241338
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
